Mouse models for pathogenic African trypanosomes: Unravelling the immunology of host-parasite-vector interactions

Parasite Immunology

Volumn 33, Issue 8, 2011, Pages 423-429

  Magez, S ^a   Caljon, G ^a,b  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b INSTITUTE OF TROPICAL MEDICINE   (Belgium)

Author keywords

Infection; Mouse model; Trypanosomiasis; Vector biology

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; TUMOR NECROSIS FACTOR; VACCINE;

AFRICAN TRYPANOSOMIASIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIGENIC VARIATION; DISEASE CARRIER; EXPERIMENTAL INFECTION; HOST PARASITE INTERACTION; HUMORAL IMMUNITY; IMMUNE SYSTEM; INFLAMMATION; NONHUMAN; PARASITE IMMUNITY; PARASITE TRANSMISSION; PARASITEMIA; PRIORITY JOURNAL; REVIEW; TREATMENT FAILURE; TRYPANOSOMA; TRYPANOSOMA RHODESIENSE; TSETSE FLY;

ANIMALS; ANTIGENIC VARIATION; CYTOKINES; DISEASE MODELS, ANIMAL; HOST-PARASITE INTERACTIONS; HUMANS; IMMUNITY, INNATE; LIPOPROTEINS, HDL; MICE; SALIVA; TRYPANOSOMA; TRYPANOSOMIASIS, AFRICAN; TSETSE FLIES;

MAMMALIA; MUS; RODENTIA;

EID: 79960429168     PISSN: 01419838     EISSN: 13653024     Source Type: Journal    
DOI: 10.1111/j.1365-3024.2011.01293.x     Document Type: Review

References (98)

1. Simarro PP, Franco JR, Ndongo P, Nguema E, Louis FJ & Jannin J. The elimination of Trypanosoma brucei gambiense sleeping sickness in the focus of Luba, Bioko Island, Equatorial Guinea. Trop Med Int Health 2006; 11: 636-646.
2. Van Den Abbeele J, Claes Y, van Bockstaele D, Le Ray D & Coosemans M. Trypanosoma brucei spp. development in the tsetse fly: characterization of the post-mesocyclic stages in the foregut and proboscis. Parasitology 1999; 118: 469-478.
3. Schofield CJ & Kabayo JP. Trypanosomiasis vector control in Africa and Latin America. Parasit Vectors 2008; 1: 24.
4. Baral TN, De Baetselier P, Brombacher F & Magez S. Control of Trypanosoma evansi infection is IgM mediated and does not require a type I inflammatory response. J Infect Dis 2007; 195: 1513-1520.
5. Lai DH, Wang QP, Li Z, Luckins AG, Reid SA & Lun ZR. Investigations into human serum sensitivity expressed by stocks of Trypanosoma brucei evansi. Int J Parasitol 2010; 40: 705-710.
6. Chamond N, Cosson A, Blom-Potar MC, et al. Trypanosoma vivax infections: pushing ahead with mouse models for the study of Nagana. I. Parasitological, hematological and pathological parameters. PLoS Negl Trop Dis 2010; 4: e792.
7. Blom-Potar MC, Chamond N, Cosson A, et al. Trypanosoma vivax infections: pushing ahead with mouse models for the study of Nagana. II. Immunobiological dysfunctions. PLoS Negl Trop Dis 2010; 4: e793.
8. + T-cells in acquired-immunity to mouse infection with Trypanosoma-equiperdum. Cell Immunol 1992; 143: 261-271.
9. Giroud C, Ottones F, Coustou V, et al. Murine Models for Trypanosoma brucei gambiense disease progression-from silent to chronic infections and early brain tropism. PLoS Negl Trop Dis 2009; 3: e509.
10. Enanga B, Burchmore RJ, Stewart ML & Barrett MP. Sleeping sickness and the brain. Cell Mol Life Sci 2002; 59: 845-858.
11. Ojok L, Kaeufer-Weiss I & Weiss E. Distribution of Trypanosoma congolense in infected multimammate rats (Mastomys coucha): light and electron microscopical studies. Vet Parasitol 2002; 105: 327-336.
12. Stockdale C, Swiderski MR, Barry JD & McCulloch R. Antigenic variation in Trypanosoma brucei: joining the DOTs. PLoS Biol 2008; 6: e185.
13. Radwanska M, Guirnalda P, De Trez C, Ryffel B, Black S & Magez S. Trypanosomiasis-induced B cell apoptosis results in loss of protective anti-parasite antibody responses and abolishment of vaccine-induced memory responses. PLoS Pathog 2008; 4: e1000078.
14. Black SJ, Guirnalda P, Frenkel D, Haynes C & Bockstal V. Induction and regulation of Trypanosoma brucei VSG-specific antibody responses. Parasitology 2010; 137: 2041-2049.
15. Van Meirvenne N, Janssens PG & Magnus E. Antigenic variation in syringe passaged populations of Trypanosoma (Trypanozoon) brucei. 1. Rationalization of the experimental approach. Ann Soc Belg Med Trop 1975; 55: 1-23.
16. Van Meirvenne N, Janssens PG, Magnus E, Lumsden WH & Herbert WJ. Antigenic variation in syringe passaged populations of Trypanosoma (Trypanozoon) brucei. II. Comparative studies on two antigenic-type collections. Ann Soc Belg Med Trop 1975; 55: 25-30.
17. Berriman M, Ghedin E, Hertz-Fowler C, et al. The genome of the African trypanosome Trypanosoma brucei. Science 2005; 309: 416-422.
18. Marcello L & Barry JD. Analysis of the VSG gene silent archive in Trypanosoma brucei reveals that mosaic gene expression is prominent in antigenic variation and is favored by archive substructure. Genome Res 2007; 17: 1344-1352.
19. McCulloch R & Horn D. What has DNA sequencing revealed about the VSG expression sites of African trypanosomes? Trends Parasitol 2009; 25: 359-363.
20. Ziegelbauer K & Overath P. Organization of 2 invariant surface glycoproteins in the surface-coat of Trypanosoma brucei. Infect Immun 1993; 61: 4540-4545.
21. Magez S, Schwegmann A, Atkinson R, et al. The role of B-cells and IgM antibodies in parasitemia, anemia, and VSG switching in Trypanosoma brucei-infected mice. PLoS Pathog 2008; 4: e1000122.
22. Dagenais TR, Freeman BE, Demick KP, Paulnock DM & Mansfield JM. Processing and presentation of variant surface glycoprotein molecules to T cells in African trypanosomiasis. J Immunol 2009; 183: 3344-3355.
23. Namangala B, Brys L, Magez S, De Baetselier P & Beschin A. Trypanosoma brucei brucei infection impairs MHC class II antigen presentation capacity of macrophages. Parasite Immunol 2000; 22: 361-370.
24. Wei GJ, Bull H, Zhou X & Table H. Intradermal infections of mice by low numbers of African trypanosomes are controlled by innate resistance but enhance susceptibility to reinfection. J Infect Dis 2011; 203: 418-429.
25. Dagenais TR, Demick KP, Bangs JD, Forest KT, Paulnock DM & Mansfield JM. T-cell responses to the trypanosome variant surface glycoprotein are not limited to hypervariable subregions. Infect Immun 2009; 77: 141-151.
26. Tabel H, Wei GJ & Shi MQ. T cells and immunopathogenesis of experimental African trypanosomiasis. Immunol Rev 2008; 225: 128-139.
27. Paulnock DM, Freeman BE & Mansfield JM. Modulation of innate immunity by African Trypanosomes. Parasitology 2010; 137: 2051-2063.
28. Magez S & Radwanska M. African trypanosomiasis and antibodies: implications for vaccination, therapy and diagnosis. Future Microbiol 2009; 4: 1075-1087.
29. Lubega GW, Ochola DO & Prichard RK. Trypanosoma brucei: anti-tubulin antibodies specifically inhibit trypanosome growth in culture. Exp Parasitol 2002; 102: 134-142.
30. Lubega GW, Byarugaba DK & Prichard RK. Immunization with a tubulin-rich preparation from Trypanosoma brucei confers broad protection against African trypanosomosis. Exp Parasitol 2002; 102: 9-22.
31. Li SQ, Yang WB, Ma LJ, et al. Immunization with recombinant actin from Trypanosoma evansi induces protective immunity against T. evansi, T. equiperdum and T. b. brucei infection. Parasitol Res 2009; 104: 429-435.
32. Li SQ, Fung MC, Reid SA, Inoue N & Lun ZR. Immunization with recombinant beta-tubulin from Trypanosoma evansi induced protection against T. evansi, T. equiperdum and T. b. brucei infection in mice. Parasite Immunol 2007; 29: 191-199.
33. Rasooly R & Balaban N. Trypanosome microtubule-associated protein p15 as a vaccine for the prevention of African sleeping sickness. Vaccine 2004; 22: 1007-1015.
34. Magez S, Geuskens M, Beschin A, et al. Specific uptake of tumor necrosis factor-alpha is involved in growth control of Trypanosoma brucei. J Cell Biol 1997; 137: 715-727.
35. Magez S, Radwanska M, Beschin A, Sekikawa K & De Baetselier P. Tumor necrosis factor alpha is a key mediator in the regulation of experimental Trypanosoma brucei infections. Infect Immun 1999; 67: 3128-3132.
36. Magez S, Radwanska M, Drennan M, et al. Interferon-gamma and nitric oxide in combination with antibodies are key protective host immune factors during Trypanosoma congolense Tc13 infections. J Infect Dis 2006; 193: 1575-1583.
37. Darji A, Lucas R, Magez S, et al. Mechanisms underlying trypanosome-elicited immunosuppression. Ann Soc Belg Med Trop 1992; 72(Suppl 1): 27-38.
38. Beschin A, Brys L, Magez S, Radwanska M & De Baetselier P. Trypanosoma brucei infection elicits nitric oxide-dependent and nitric oxide-independent suppressive mechanisms. J Leukoc Biol 1998; 63: 429-439.
39. Beutler B, Mahoney J, Le Trang N, Pekala P & Cerami A. Purification of cachectin, a lipoprotein lipase-suppressing hormone secreted by endotoxin-induced RAW 264.7 cells. J Exp Med 1985; 161: 984-995.
40. Beutler B & Cerami A. Cachectin and tumour necrosis factor as two sides of the same biological coin. Nature 1986; 320: 584-588.
41. Daulouede S, Bouteille B, Moynet D, et al. Human macrophage tumor necrosis factor (TNF)-alpha production induced by Trypanosoma brucei gambiense and the role of TNF-alpha in parasite control. J Infect Dis 2001; 183: 988-991.
42. Magez S, Radwanska M, Drennan M, et al. Tumor necrosis factor (TNF) receptor-1 (TNFp55) signal transduction and macrophage-derived soluble TNF are crucial for nitric oxide-mediated Trypanosoma congolense parasite killing. J Infect Dis 2007; 196: 954-962.
43. Darji A, Beschin A, Sileghem M, Heremans H, Brys L & De Baetselier P. In vitro simulation of immunosuppression caused by Trypanosoma brucei: active involvement of gamma interferon and tumor necrosis factor in the pathway of suppression. Infect Immun 1996; 64: 1937-1943.
44. Hertz CJ, Filutowicz H & Mansfield JM. Resistance to the African trypanosomes is IFN-gamma dependent. J Immunol 1998; 161: 6775-6783.
45. Guilliams M, Oldenhove G, Noel W, et al. African trypanosomiasis: naturally occurring regulatory T cells favor trypanotolerance by limiting pathology associated with sustained type 1 inflammation. J Immunol 2007; 179: 2748-2757.
46. Morrison LJ, McLellan S, Sweeney L, et al. Role for parasite genetic diversity in differential host responses to Trypanosoma brucei infection. Infect Immun 2010; 78: 1096-1108.
47. Namangala B, De Baetselier P & Beschin A. Both type-I and type-II responses contribute to murine trypanotolerance. J Vet Med Sci 2009; 71: 313-318.
48. Namangala B, Noel W, De Baetselier P, Brys L & Beschin A. Relative contribution of interferon-gamma and interleukin-10 to resistance to murine African trypanosomosis. J Infect Dis 2001; 183: 1794-1800.
49. Magez S, Stijlemans B, Radwanska M, Pays E, Ferguson MA & De Baetselier P. The glycosyl-inositol-phosphate and dimyristoylglycerol moieties of the glycosylphosphatidylinositol anchor of the trypanosome variant-specific surface glycoprotein are distinct macrophage-activating factors. J Immunol 1998; 160: 1949-1956.
50. Magez S, Stijlemans B, Baral T & De Baetselier P. VSG-GPI anchors of African trypanosomes: their role in macrophage activation and induction of infection-associated immunopathology. Microbes Infect 2002; 4: 999-1006.
51. Guilliams M, Movahedi K, Bosschaerts T, et al. IL-10 dampens TNF/inducible nitric oxide synthase-producing dendritic cell-mediated pathogenicity during parasitic infection. J Immunol 2009; 182: 1107-1118.
52. - cells in the production of IL-4, IL-10, and IFN-gamma and in trypanosome-elicited immunosuppression. J Immunol 1998; 161: 6189-6197.
53. Olsson T, Bakhiet M, Hojeberg B, et al. CD8 is critically involved in lymphocyte activation by a T. brucei brucei-released molecule. Cell 1993; 72: 715-727.
54. Bosschaerts T, Guilliams M, Noel W, et al. Alternatively activated myeloid cells limit pathogenicity associated with African trypanosomiasis through the IL-10 inducible gene selenoprotein P. J Immunol 2008; 180: 6168-6175.
55. Sileghem M, Flynn JN, Logan-Henfrey L & Ellis J. Tumour necrosis factor production by monocytes from cattle infected with Trypanosoma (Duttonella) vivax and Trypanosoma (Nannomonas) congolense: possible association with severity of anaemia associated with the disease. Parasite Immunol 1994; 16: 51-54.
56. Masocha W, Robertson B, Rottenberg ME, Mhlanga J, Sorokin L & Kristensson K. Cerebral vessel laminins and IFN-gamma define Trypanosoma brucei brucei penetration of the blood-brain barrier. J Clin Invest 2004; 114: 689-694.
57. Yoshihara K, Morris A, Iraqi F & Naessens J. Cytokine mRNA profiles in bovine macrophages stimulated with Trypanosoma congolense. J Vet Med Sci 2007; 69: 421-423.
58. Maclean L, Odiit M & Sternberg JM. Intrathecal cytokine responses in Trypanosoma brucei rhodesiense sleeping sickness patients. Trans R Soc Trop Med Hyg 2006; 100: 270-275.
59. Ngotho M, Kagira JM, Jensen HE, Karanja SM, Farah IO & Hau J. Immunospecific immunoglobulins and IL-10 as markers for Trypanosoma brucei rhodesiense late stage disease in experimentally infected vervet monkeys. Trop Med Int Health 2009; 14: 736-747.
60. Van Meirvenne N, Maginus E & Janssens PG. The effect of normal human serum on trypanosomes of distinct antigenic type (ETat 1 to 12) isolated from a strain of Trypanosoma brucei rhodesiense. Ann Soc Belg Med Trop 1976; 56: 55-63.
61. De Greef C, Imberechts H, Matthyssens G, Van Meirvenne N & Hamers R. A gene expressed only in serum-resistant variants of Trypanosoma brucei rhodesiense. Mol Biochem Parasitol 1989; 36: 169-176.
62. Xong HV, Vanhamme L, Chamekh M, et al. A VSG expression site-associated gene confers resistance to human serum in Trypanosoma rhodesiense. Cell 1998; 95: 839-846.
63. Raper J, Fung R, Ghiso J, Nussenzweig V & Tomlinson S. Characterization of a novel trypanosome lytic factor from human serum. Infect Immun 1999; 67: 1910-1916.
64. Thomson R, Samanovic M & Raper J. Activity of trypanosome lytic factor: a novel component of innate immunity. Future Microbiol 2009; 4: 789-796.
65. Thomson R, Molina-Portela P, Mott H, Carrington M & Raper J. Hydrodynamic gene delivery of baboon trypanosome lytic factor eliminates both animal and human-infective African trypanosomes. Proc Natl Acad Sci U S A 2009; 106: 19509-19514.
66. Kieft R, Capewell P, Turner CMR, Veitch NJ, Macleod A & Hajduk S. Mechanism of Trypanosoma brucei gambiense (group 1) resistance to human trypanosome lytic factor. Proc Natl Acad Sci USA 2010; 107: 16137-16141.
67. Van Den Abbeele J, Caljon G, De Ridder K, De Baetselier P & Coosemans M. Trypanosoma brucei modifies the tsetse salivary composition, altering the fly feeding behavior that favors parasite transmission. PLoS Pathog 2010; 6: e1000926.
68. Alves-Silva J, Ribeiro JM, Van Den AJ, et al. An insight into the sialome of Glossina morsitans morsitans. BMC Genomics 2010; 11: 213.
69. Caljon G, De Ridder K, De Baetselier P, Coosemans M & Van Den Abbeele J. Identification of a tsetse fly salivary protein with dual inhibitory action on human platelet aggregation. PLoS ONE 2010; 5: e9671.
70. Van Den Abbeele J, Caljon G, Dierick JF, Moens L, De Ridder K & Coosemans M. The Glossina morsitans tsetse fly saliva: general characteristics and identification of novel salivary proteins. Insect Biochem Mol Biol 2007; 37: 1075-1085.
71. Caljon G, Van Den Abbeele J, Stijlemans B, Coosemans M, De Baetselier P & Magez S. Tsetse fly saliva accelerates the onset of Trypanosoma brucei infection in a mouse model associated with a reduced host inflammatory response. Infect Immun 2006; 74: 6324-6330.
72. Belkaid Y, Kamhawi S, Modi G, et al. Development of a natural model of cutaneous leishmaniasis: powerful effects of vector saliva and saliva preexposure on the long-term outcome of Leishmania major infection in the mouse ear dermis. J Exp Med 1998; 188: 1941-1953.
73. Titus RG & Ribeiro JMC. Salivary-gland lysates from the sand fly Lutzomyia longipalpis enhance Leishmania infectivity. Science 1988; 239: 1306-1308.
74. Styer LM, Lim PY, Louie KL, Albright RG, Kramer LD & Bernard KA. Mosquito saliva causes enhancement of West Nile virus infection in mice. J Virol 2011; 85: 1517-1527.
75. Schneider BS & Higgs S. The enhancement of arbovirus transmission and disease by mosquito saliva is associated with modulation of the host immune response. Trans R Soc Trop Med Hyg 2008; 102: 400-408.
76. Ramamoorthi N, Narasimhan S, Pal U, et al. The Lyme disease agent exploits a tick protein to infect the mammalian host. Nature 2005; 436: 573-577.
77. Rosa P. Lyme disease agent borrows a practical coat. Nat Med 2005; 11: 831-832.
78. Norsworthy NB, Sun JR, Elnaiem D, Lanzaro G & Soong L. Sand fly saliva enhances Leishmania amazonensis infection by modulation interleukin-10 production. Infect Immun 2004; 72: 1240-1247.
79. Hall LR & Titus RG. Sand fly vector saliva selectively modulates macrophage functions that inhibit killing of Leishmania major and nitric-oxide production. J Immunol 1995; 155: 3501-3506.
80. Ader DB, Celluzzi C, Bisbing J, et al. Modulation of Dengue virus infection of dendritic cells by Aedes aegypti saliva. Viral Immunol 2004; 17: 252-265.
81. Hovius JW, de Jong MA, den Dunnen J, et al. Salp15 binding to DC-SIGN inhibits cytokine expression by impairing both nucleosome remodeling and mRNA stabilization. PLoS Pathog 2008; 4: e31.
82. Prevot PP, Beschin A, Lins L, et al. Exosites mediate the anti-inflammatory effects of a multifunctional serpin from the saliva of the tick Ixodes ricinus. FEBS J 2009; 276: 3235-3246.
83. Gounaris K & Selkirk ME. Parasite nucleotide-metabolizing enzymes and host purinergic signalling. Trends Parasitol 2005; 21: 17-21.
84. Ribeiro JMC & Mather TN. Ixodes scapularis: salivary kininase activity is a metallo dipeptidyl carboxypeptidase. Exp Parasitol 1998; 89: 213-221.
85. Ribeiro JMC & Spielman A. Ixodes dammini- salivary anaphylatoxin inactivating activity. Exp Parasitol 1986; 62: 292-297.
86. Deruaz M, Frauenschuh A, Alessandri AL, et al. Ticks produce highly selective chemokine binding proteins with antiinflammatory activity. J Exp Med 2008; 205: 2019-2031.
87. Calvo E, Mans BJ, Ribeiro JMC & Andersen JF. Multifunctionality and mechanism of ligand binding in a mosquito antiinflammatory protein. Proc Natl Acad Sci USA 2009; 106: 3728-3733.
88. Couvreur B, Beaufays J, Charon C, et al. Variability and action mechanism of a family of anticomplement proteins in Ixodes ricinus. PLoS ONE 2008; 3: e1400.
89. Paesen GC, Adams PL, Harlos K, Nuttall PA & Stuart DI. Tick histamine-binding proteins: isolation, cloning, and three-dimensional structure. Mol Cell 1999; 3: 661-671.
90. Ribeiro JMC & Walker FA. High-affinity histamine-binding and antihistaminic activity of the salivary nitric oxide-carrying heme protein (nitrophorin) of Rhodnius prolixus. J Exp Med 1994; 180: 2251-2257.
91. Caljon G, Van Den Abbeele J, Sternberg JM, Coosemans M, De Baetselier P & Magez S. Tsetse fly saliva biases the immune response to Th2 and induces anti-vector antibodies that are a useful tool for exposure assessment. Int J Parasitol 2006; 36: 1025-1035.
92. Theodos CM, Ribeiro JM & Titus RG. Analysis of enhancing effect of sand fly saliva on Leishmania infection in mice. Infect Immun 1991; 59: 1592-1598.
93. Kamhawi S, Belkaid Y, Modi G, Rowton E & Sacks D. Protection against cutaneous leishmaniasis resulting from bites of uninfected sand flies. Science 2000; 290: 1351-1354.
94. Valenzuela JG, Belkaid Y, Garfield MK, et al. Toward a defined anti-Leishmania vaccine targeting vector antigens: characterization of a protective salivary protein. J Exp Med 2001; 194: 331-342.
95. Caljon G, Broos K, De Goeyse I, et al. Identification of a functional Antigen5-related allergen in the saliva of a blood feeding insect, the tsetse fly. Insect Biochem Mol Biol 2009; 39: 332-341.
96. Poinsignon A, Cornelie S, Remoue F, et al. Human/vector relationships during human African trypanosomiasis: initial screening of immunogenic salivary proteins of Glossina species. Am J Trop Med Hyg 2007; 76: 327-333.
97. Ellis JA, Shapiro SZ, Ole Moi-Yoi O & Moloo SK. Lesions and saliva-specific antibody responses in rabbits with immediate and delayed hypersensitivity reactions to the bites of Glossina morsitans centralis. Vet Pathol 1986; 23: 661-667.
98. Poinsignon A, Remoue F, Rossignol M, et al. Human IgG antibody response to glossina saliva: an epidemiologic marker of exposure to Glossina bites. Am J Trop Med Hyg 2008; 78: 750-753.